Rocket Pharmaceuticals is trading at $2.33 (-5.85%) during the October 13 session; a reported 2.01% biotech-sector decline may be contributing, but does not establish the precise cause. - Sector commentary identified no single clear catalyst. - No clear negative company-specific announcement was found. Recent coverage described Goldman Sachs raising its rating to Neutral, while Jefferies cut its price target earlier in October.